These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 26077412

  • 1. Anti-tumor Necrosis Factor Therapy Increased Spine and Femoral Neck Bone Mineral Density of Patients with Active Ankylosing Spondylitis with Low Bone Mineral Density.
    Li H, Li Q, Chen X, Ji C, Gu J.
    J Rheumatol; 2015 Aug; 42(8):1413-7. PubMed ID: 26077412
    [Abstract] [Full Text] [Related]

  • 2. Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study.
    van der Weijden MA, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE.
    J Rheumatol; 2016 Apr; 43(4):758-64. PubMed ID: 26879348
    [Abstract] [Full Text] [Related]

  • 3. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study.
    Durnez A, Paternotte S, Fechtenbaum J, Landewé RB, Dougados M, Roux C, Briot K.
    J Rheumatol; 2013 Oct; 40(10):1712-8. PubMed ID: 23950191
    [Abstract] [Full Text] [Related]

  • 4. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis.
    Kang KY, Ju JH, Park SH, Kim HY.
    Rheumatology (Oxford); 2013 Apr; 52(4):718-26. PubMed ID: 23275389
    [Abstract] [Full Text] [Related]

  • 5. [Effect of tumour necrosis factor α blockade on bone metabolism in chronic inflammatory joint diseases].
    Aguilar Del Rey FJ, García Portales R, Haro Liger M, Rodríguez Andreu J, Casals Sánchez JL, Pérez González R.
    Med Clin (Barc); 2016 Jul 15; 147(2):56-62. PubMed ID: 27209224
    [Abstract] [Full Text] [Related]

  • 6. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U, Teichmann J, Müller-Ladner U, Strunk J.
    Rheumatology (Oxford); 2005 Dec 15; 44(12):1546-8. PubMed ID: 16263785
    [Abstract] [Full Text] [Related]

  • 7. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.
    Gulyás K, Horváth Á, Végh E, Pusztai A, Szentpétery Á, Pethö Z, Váncsa A, Bodnár N, Csomor P, Hamar A, Bodoki L, Bhattoa HP, Juhász B, Nagy Z, Hodosi K, Karosi T, FitzGerald O, Szücs G, Szekanecz Z, Szamosi S, Szántó S.
    Clin Rheumatol; 2020 Jan 15; 39(1):167-175. PubMed ID: 31522318
    [Abstract] [Full Text] [Related]

  • 8. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis.
    Haroon NN, Sriganthan J, Al Ghanim N, Inman RD, Cheung AM.
    Semin Arthritis Rheum; 2014 Oct 15; 44(2):155-61. PubMed ID: 24909809
    [Abstract] [Full Text] [Related]

  • 9. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
    Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H, Gunay N, Akkoc N.
    BMC Musculoskelet Disord; 2012 Oct 02; 13():191. PubMed ID: 23025387
    [Abstract] [Full Text] [Related]

  • 10. Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.
    Braun J, Buehring B, Baraliakos X, Gensler LS, Porter B, Quebe-Fehling E, Haemmerle S.
    BMC Musculoskelet Disord; 2021 Dec 13; 22(1):1037. PubMed ID: 34903218
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
    Kim HR, Lee SH, Kim HY.
    Rheumatology (Oxford); 2006 Oct 13; 45(10):1197-200. PubMed ID: 16567356
    [Abstract] [Full Text] [Related]

  • 13. Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis.
    Orsolini G, Adami G, Adami S, Viapiana O, Idolazzi L, Gatti D, Rossini M.
    Calcif Tissue Int; 2016 Jun 13; 98(6):580-5. PubMed ID: 26887973
    [Abstract] [Full Text] [Related]

  • 14. Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study.
    Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T.
    Rheumatol Int; 2018 May 13; 38(5):777-784. PubMed ID: 29294175
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A, McKenna MJ, Murray BF, Ng CT, Brady JJ, Morrin M, Radovits B, Veale DJ, Fitzgerald O.
    J Rheumatol; 2013 May 13; 40(5):653-62. PubMed ID: 23457381
    [Abstract] [Full Text] [Related]

  • 17. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
    Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH, Kloppenborg PW.
    J Clin Endocrinol Metab; 1995 Oct 13; 80(10):2859-65. PubMed ID: 7559865
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.